OBJECTIVE: To analyse the immunohistochemical and mRNA expression of SWI/SNF (SWItch/Sucrose NonFermentable) complex subunit polybromo-1 (PBRM1) in clear cell renal cell carcinoma (ccRCC) and its impact on clinical outcomes. PATIENTS AND METHODS: In all, 213 consecutive patients treated surgically for renal cell carcinoma (RCC) between 1992 and 2009 were selected. A single pathologist reviewed all cases to effect a uniform reclassification and determined the most representative tumour areas for construction of a tissue microarray. In addition, mRNA expression of PBRM1 was analysed by reverse transcriptase-polymerase chain reaction. RESULTS: Of the 112-immunostained ccRCC specimens, 34 (30.4%) were PBRM1-negative, and 78 (69.6%) were PBRM1-positive. The protein expression of PBRM1 was associated with tumour stage (P < 0.001), clinical stage (P < 0.001), pN stage (P = 0.035) and tumour size (P = 0.002). PBRM1 mRNA expression was associated with clinical stage (P = 0.023), perinephric fat invasion (P = 0.008) and lymphovascular invasion (P = 0.042). PBRM1 significantly influenced tumour recurrence and tumour-related death. Disease-specific survival rates for patients whose specimens showed positive- and negative-PBRM1 expression were 89.7% and 70.6%, respectively (P = 0.017). Recurrence-free survival rates in patients with positive- and negative-expression of PBRM1 were 87.3% and 66.7%, respectively (P = 0.048). CONCLUSIONS: PBRM1-negative expression is a markedly poor prognosis event in ccRCC. We encourage PBRM1 study by other groups in order to validate our findings and confirm its possible role as a useful marker in the management of patients with ccRCC.
OBJECTIVE: To analyse the immunohistochemical and mRNA expression of SWI/SNF (SWItch/Sucrose NonFermentable) complex subunit polybromo-1 (PBRM1) in clear cell renal cell carcinoma (ccRCC) and its impact on clinical outcomes. PATIENTS AND METHODS: In all, 213 consecutive patients treated surgically for renal cell carcinoma (RCC) between 1992 and 2009 were selected. A single pathologist reviewed all cases to effect a uniform reclassification and determined the most representative tumour areas for construction of a tissue microarray. In addition, mRNA expression of PBRM1 was analysed by reverse transcriptase-polymerase chain reaction. RESULTS: Of the 112-immunostained ccRCC specimens, 34 (30.4%) were PBRM1-negative, and 78 (69.6%) were PBRM1-positive. The protein expression of PBRM1 was associated with tumour stage (P < 0.001), clinical stage (P < 0.001), pN stage (P = 0.035) and tumour size (P = 0.002). PBRM1 mRNA expression was associated with clinical stage (P = 0.023), perinephric fat invasion (P = 0.008) and lymphovascular invasion (P = 0.042). PBRM1 significantly influenced tumour recurrence and tumour-related death. Disease-specific survival rates for patients whose specimens showed positive- and negative-PBRM1 expression were 89.7% and 70.6%, respectively (P = 0.017). Recurrence-free survival rates in patients with positive- and negative-expression of PBRM1 were 87.3% and 66.7%, respectively (P = 0.048). CONCLUSIONS:PBRM1-negative expression is a markedly poor prognosis event in ccRCC. We encourage PBRM1 study by other groups in order to validate our findings and confirm its possible role as a useful marker in the management of patients with ccRCC.
Authors: Brandon John Manley; Emily C Zabor; Jozefina Casuscelli; Daniel M Tennenbaum; Almedina Redzematovic; Maria F Becerra; Nicole Benfante; Yusuke Sato; Teppei Morikawa; Haruki Kume; Masashi Fukayama; Yukio Homma; Seishi Ogawa; Maria E Arcila; Martin H Voss; Darren R Feldman; Jonathan A Coleman; Victor E Reuter; Robert J Motzer; Paul Russo; James J Hsieh; A Ari Hakimi Journal: Eur Urol Focus Date: 2016-07-16
Authors: Thai H Ho; Payal Kapur; Richard W Joseph; Daniel J Serie; Jeanette E Eckel-Passow; Mansi Parasramka; John C Cheville; Kevin J Wu; Eugene Frenkel; Dinesh Rakheja; Karoliina Stefanius; James Brugarolas; Alexander S Parker Journal: Urol Oncol Date: 2014-11-24 Impact factor: 3.498
Authors: Jatinder K Lamba; Stanley Pounds; Xueyuan Cao; Kristine R Crews; Christopher R Cogle; Neha Bhise; Susana C Raimondi; James R Downing; Sharyn D Baker; Raul C Ribeiro; Jeffrey E Rubnitz Journal: Leuk Lymphoma Date: 2015-10-16
Authors: Richard W Joseph; Payal Kapur; Daniel J Serie; Mansi Parasramka; Thai H Ho; John C Cheville; Eugene Frenkel; Alexander S Parker; James Brugarolas Journal: J Urol Date: 2015-08-20 Impact factor: 7.450